Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Healthcare
Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Knight Therapeutics Inc > Cheap Valuation
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(3)
•••
Comment by porksnifferon Jan 31, 2023 12:23pm
109 Views
Post# 35257099

RE:RE:RE:RE:RE:RE:RE:Cheap Valuation

RE:RE:RE:RE:RE:RE:RE:Cheap Valuation
curiousj wrote: I appreciate the devil's advocate role you play... would you disagree that this is already priced in by investors?

Also, what are you looking for to buy GUD? if you're not interested in buying, are you short GUD and what would make you positive?



This stock was driven to over $11 by investors relying on PAST performance of a LUCKY CEO. He even admitted he got lucky.

Now you and and everyone else on this board is trapped like a rat in some stock that sells old drugs tossed away by their creators. What is priced in is what is known today. The markets they sell to are unstable.

I, like you got trapped. But I sold out over a year ago for a bit more than current price, booked a loss and promptly doubled my money elsewhere. Liberating and profitable. You would be wise to do the same. Unlike Chianchin, I am not as polite; MugMod should be investigated for the pumping and frauds he's committed. I hope you are not being influenced by his pumping. He has been wrong for 10 years. While Chianchin and other bears have got it spot on. This is a loser stock, the CEO was already a billionaire and retired. His wealth does not depend on this stock. Your does. Let that sink in. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities